Anil Nalluri’s Post

View profile for Anil Nalluri, graphic

Co-Founder & Director of Sales and Client Services at QvalFocus Inc.

Industry leaders, the FDA has released a guidance draft document on data integrity for in-vivo bioavailability and bioequivalence studies. This document is now open for comments. Data integrity is a critical component to ensure the accuracy of data submitted for INDA and NDA's, and the FDA guidelines on this are very welcoming. Certain data handling practices in CROs have always been questioned by authorities, making this guidance document a crucial step in ensuring the integrity of data in the industry. Share your thoughts and comments on this important topic. QvalFocus #IndustryLeaders #DataIntegrity #Bioavailability #Bioequivalence #FDA #CROs Follow us at #QvalFocus for current trends and jobs in the industry.

To view or add a comment, sign in

Explore topics